Ikena Oncology is again shrinking its herd and signaling a tough fight ahead as one of two assets, a TEAD1-selective Hippo pathway inhibitor, is cut. The cancer biotech is laying off more than half of ...
ROCHESTER, N.Y. — One of Rochester’s largest employers, Paychex, is cutting its local workforce. The payroll company confirms what it calls a “reprioritization” of the company. A spokesperson for the ...
One of Rochester’s largest employers, Paychex, Inc., laid off some employees last week. In an emailed statement, the company confirmed the move, writing: “We are continuously reprioritizing roles ...
I rate Rocket Pharmaceuticals a hold, given its strategic shift to late-stage AAV cardiovascular therapies and disciplined capital allocation. The company is cutting costs, reducing staff by 30%, and ...
On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults ...
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the strategic ...
Cellectar Biosciences (CLRB) announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic ...
UTRECHT, The Netherlands and PHILADELPHIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results